

## HM-52L: Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin Lymphomas: Summarizing Current Efficacy and Safety Data

### Toolkit

#### Introduction: Overview of B Cell Non-Hodgkin Lymphomas

Reference	URL
American Cancer Society (ACS). Key statistics for non-Hodgkin lymphoma. 2023.	<a href="https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html">https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html</a>
Armitage JO, et al. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. <i>J Clin Oncol</i> . 1998;16:2780-2795.	<a href="https://ascopubs.org/doi/10.1200/JCO.1998.16.8.2780">https://ascopubs.org/doi/10.1200/JCO.1998.16.8.2780</a>
Abramson JS, et al. Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. <i>Blood</i> . 2005;106:1164-1174.	<a href="https://ashpublications.org/blood/article/106/4/1164/21561/Advances-in-the-biology-and-therapy-of-diffuse">https://ashpublications.org/blood/article/106/4/1164/21561/Advances-in-the-biology-and-therapy-of-diffuse</a>
Baeuerle PA, et al. Bispecific T-cell engaging antibodies for cancer therapy. <i>Cancer Res</i> . 2009 Jun 15;69(12):4941-4.	<a href="https://aacrjournals.org/cancerres/article/69/12/4941/549633/Bispecific-T-Cell-Engaging-Antibodies-for-Cancer">https://aacrjournals.org/cancerres/article/69/12/4941/549633/Bispecific-T-Cell-Engaging-Antibodies-for-Cancer</a>
Cerhan JR. Epidemiology of Follicular Lymphoma. <i>Hematol Oncol Clin North Am</i> . 2020;34:631-646.	<a href="https://www.sciencedirect.com/science/article/abs/pii/S0889858820300265">https://www.sciencedirect.com/science/article/abs/pii/S0889858820300265</a>
Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med</i> . 2002;346:235-242.	<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa011795">https://www.nejm.org/doi/full/10.1056/NEJMoa011795</a>
Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. <i>Blood</i> . 2010;116:2040-2045.	<a href="https://ashpublications.org/blood/article/116/12/2040/27477/Long-term-outcome-of-patients-in-the-LNH-98-5">https://ashpublications.org/blood/article/116/12/2040/27477/Long-term-outcome-of-patients-in-the-LNH-98-5</a>
Dunleavy K. Aggressive B cell lymphoma: Optimal therapy for MYC-positive, double-hit, and triple-hit DLBCL. <i>Curr Treat Options Oncol</i> . 2015;16:58.	<a href="https://link.springer.com/article/10.1007/s11864-015-0374-0">https://link.springer.com/article/10.1007/s11864-015-0374-0</a>
Inamdar A, et al. <i>Oncotarget</i> . 2016;7(30):48692-48731.	<a href="https://www.oncotarget.com/article/8961/text/">https://www.oncotarget.com/article/8961/text/</a>
Lynch DT, et al. Mantle cell lymphoma. <i>StatPearls</i> . July 28, 2023.	<a href="https://www.ncbi.nlm.nih.gov/books/NBK536985/">https://www.ncbi.nlm.nih.gov/books/NBK536985/</a>
National Cancer Institute (NCI). Cancer Stat Facts: NHL—Follicular Lymphoma.	<a href="https://seer.cancer.gov/statfacts/html/follicular.html">https://seer.cancer.gov/statfacts/html/follicular.html</a>
Pavlasova G, et al. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. <i>Haematologica</i> . 2020 Jun;105(6):1494-1506.	<a href="https://haematologica.org/article/view/9425">https://haematologica.org/article/view/9425</a>
Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. <i>Am J Transplant</i> . 2006;6:859-866.	<a href="https://www.amjtransplant.org/article/S1600-6135(22)02663-6/fulltext">https://www.amjtransplant.org/article/S1600-6135(22)02663-6/fulltext</a>
Schmitz R, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. <i>N Engl J Med</i> . 2018;378:1396-1407.	<a href="https://www.nejm.org/doi/10.1056/NEJMoa1801445">https://www.nejm.org/doi/10.1056/NEJMoa1801445</a>

## Bispecific Antibodies in B Cell NHL Therapy: Current State, Future Potential, and Adverse Event Profile

Reference	URL
AssayGenie. COVID-19 cytokine storm multiplex assays.	<a href="https://www.assaygenie.com/cytokine-storm-multiplex-assays">https://www.assaygenie.com/cytokine-storm-multiplex-assays</a>
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy (Celestimo). ClinicalTrials.gov identifier: NCT04712097. Updated September 6, 2023.	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT04712097">https://classic.clinicaltrials.gov/ct2/show/NCT04712097</a>
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2). ClinicalTrials.gov identifier: NCT03888105. Updated April 20, 2023.	<a href="https://classic.clinicaltrials.gov/ct2/show/NCT03888105">https://classic.clinicaltrials.gov/ct2/show/NCT03888105</a>
Bannerji R, et al. Odronextamab (REGN1979), a human CD20 x CD3 bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-Hodgkin lymphoma, including patients refractory to CAR T therapy. <i>Blood</i> . 2020;136(suppl 1):42-43.	<a href="https://www.sciencedirect.com/science/article/pii/S006497118696065">https://www.sciencedirect.com/science/article/pii/S006497118696065</a>
Bannerji R, et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. <i>Lancet Haematol</i> . 2022;9:e327-e339.	<a href="https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00072-2/fulltext">https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00072-2/fulltext</a>
Budde LE, Assouline S, Sehn LH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. <i>J Clin Oncol</i> . 2022;40:481-491.	<a href="https://ascopubs.org/doi/10.1200/JCO.21.00931">https://ascopubs.org/doi/10.1200/JCO.21.00931</a>
Budde LE, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study. <i>Lancet Oncol</i> . 2022;23:1055-1065.	<a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00335-7/fulltext">https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00335-7/fulltext</a>
Chiu C, et al. Evaluation of pharmacodynamic biomarkers of epcoritamab (GEN3013; CD3XCD20): Results from a phase 1/2 dose-escalation study in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Presented at the 25 <sup>th</sup> Congress of the European Hematology Association; June 11-21, 2020. EHA Library. 2020:EP1330.	<a href="https://library.ehaweb.org/eha/2020/eha25th/293817/christopher.chiu.evaluation.of.pharmacodynamic.biomarkers.of.epcoritamab.html">https://library.ehaweb.org/eha/2020/eha25th/293817/christopher.chiu.evaluation.of.pharmacodynamic.biomarkers.of.epcoritamab.html</a>

Reference	URL
Casulo C, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study. <i>J Clin Oncol.</i> 2015;33:2516-2522.	<a href="https://ascopubs.org/doi/10.1200/JCO.2014.59.7534">https://ascopubs.org/doi/10.1200/JCO.2014.59.7534</a>
Dickinson MJ, et al. EHA 2020; Abstract S241	<a href="https://library.ehaweb.org/eha/2020/eha25th/293690/michael.j.dickinson.cd20-tcb.in.relapsed.or.refractory.non-hodgkin.lymphoma.html">https://library.ehaweb.org/eha/2020/eha25th/293690/michael.j.dickinson.cd20-tcb.in.relapsed.or.refractory.non-hodgkin.lymphoma.html</a>
Dickinson MJ, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. <i>N Engl J Med.</i> 2022;387:2220-2231.	<a href="https://www.nejm.org/doi/10.1056/NEJMoa2206913">https://www.nejm.org/doi/10.1056/NEJMoa2206913</a>
Dickinson M, et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and $\geq 2$ prior therapies: Pivotal phase II expansion results. <i>J Clin Oncol.</i> 2022;40(16 suppl):7500.	<a href="https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7500">https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7500</a>
Engelberts PJ, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. <i>EBioMedicine.</i> 2020;52:102625.	<a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30840-0/fulltext">https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30840-0/fulltext</a>
González Barca E. Role of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma in the CART era. <i>Front Immunol.</i> 2022;13:909008.	<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2022.909008/full">https://www.frontiersin.org/articles/10.3389/fimmu.2022.909008/full</a>
Hosseini I, et al. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: Impact of translational system modeling. <i>NPJ Syst Biol Appl.</i> 2020;6:28.	<a href="https://www.nature.com/articles/s41540-020-00145-7">https://www.nature.com/articles/s41540-020-00145-7</a>
Hutchings M, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. <i>J Clin Oncol.</i> 2021;39:1959-1970.	<a href="https://ascopubs.org/doi/10.1200/JCO.20.03175">https://ascopubs.org/doi/10.1200/JCO.20.03175</a>
Hutchings M, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: Updated dose escalation data. <i>Blood.</i> 2020;136(suppl 1):45-46.	<a href="https://ashpublications.org/blood/article/136/Supplement%201/45/470017/Subcutaneous-Epcoritamab-Induces-Complete">https://ashpublications.org/blood/article/136/Supplement%201/45/470017/Subcutaneous-Epcoritamab-Induces-Complete</a>
Hutchings M, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. <i>Lancet.</i> 2021;398:1157-1169.	<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00889-8/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00889-8/fulltext</a>
fKim TM, et al. A phase 2 study of odronextamab (REGN1979), a CD20 x CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood.</i> 2020;136(suppl 1):28-29.	<a href="https://ashpublications.org/blood/article/136/Supplement%201/28/472688/A-Phase-2-Study-of-Odronextamab-REGN1979-a-CD20-x">https://ashpublications.org/blood/article/136/Supplement%201/28/472688/A-Phase-2-Study-of-Odronextamab-REGN1979-a-CD20-x</a>

Reference	URL
Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> . 2014;124:188-195.	<a href="https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management">https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management</a>
Lee DW, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol Blood Marrow Transplant</i> . 2019;25:625-638.	<a href="https://www.astctjournal.org/article/S1083-8791(18)31691-4/fulltext">https://www.astctjournal.org/article/S1083-8791(18)31691-4/fulltext</a>
Link BK, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: Data from the observational National LymphoCare Study. <i>Br J Haematol</i> . 2019;184:660-663.	<a href="https://onlinelibrary.wiley.com/doi/10.1111/bjh.15149">https://onlinelibrary.wiley.com/doi/10.1111/bjh.15149</a>
Minson A, et al. Glofitamab CD20-TCB bispecific antibody. <i>Leuk Lymphoma</i> . 2021;62:3098-3108.	<a href="https://www.tandfonline.com/doi/abs/10.1080/10428194.2021.1953016">https://www.tandfonline.com/doi/abs/10.1080/10428194.2021.1953016</a>
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphoma. Version 5.2023.	<a href="https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf">https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</a>
Neelapu SS, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. <i>Nat Rev Clin Oncol</i> . 2018;15:47-62.	<a href="https://www.nature.com/articles/nrclinonc.2017.148">https://www.nature.com/articles/nrclinonc.2017.148</a>
Nie S, et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics. <i>Antib Ther</i> . 2020;3:18-62.	<a href="https://academic.oup.com/abt/article/3/1/18/5739255">https://academic.oup.com/abt/article/3/1/18/5739255</a>
Phillips T, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Presented at the 64th ASH Annual Meeting; December 10–13, 2022.	<a href="https://medically.gene.com/global/en/unrestricted/hematology/ASH-2022/ash-2022-presentation-phillips-glofitamab-monotherapy-i.html">https://medically.gene.com/global/en/unrestricted/hematology/ASH-2022/ash-2022-presentation-phillips-glofitamab-monotherapy-i.html</a>
Phillips T, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. <i>Blood</i> . 2022;140(suppl 1):178-180.	<a href="https://ashpublications.org/blood/article/140/Supplement%201/178/489039/Glofitamab-Monotherapy-Induces-High-Complete">https://ashpublications.org/blood/article/140/Supplement%201/178/489039/Glofitamab-Monotherapy-Induces-High-Complete</a>
Schuster SJ, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. <i>Blood</i> . 2019;134(suppl 1):6.	<a href="https://ashpublications.org/blood/article/134/Supplement_1/6/427814/Mosunetuzumab-Induces-Complete-Remissions-in-Poor">https://ashpublications.org/blood/article/134/Supplement_1/6/427814/Mosunetuzumab-Induces-Complete-Remissions-in-Poor</a>
Smith EJ, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. <i>Sci Rep</i> . 2015;5:17943.	<a href="https://www.nature.com/articles/srep17943">https://www.nature.com/articles/srep17943</a>
Subklewe M. <i>Blood Adv</i> . 2021;5(2):607-612.	<a href="https://ashpublications.org/bloodadvances/article/5/2/607/475005/BiTEs-better-than-CAR-T-cells">https://ashpublications.org/bloodadvances/article/5/2/607/475005/BiTEs-better-than-CAR-T-cells</a>
Sun LL, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. <i>Sci Transl Med</i> . 2015;7:287ra70.	<a href="https://www.science.org/doi/10.1126/scitranslmed.aaa4802">https://www.science.org/doi/10.1126/scitranslmed.aaa4802</a>

Reference	URL
Thieblemont C, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II Trial. <i>J Clin Oncol.</i> 2023;41:2238-2247.	<a href="https://ascopubs.org/doi/10.1200/JCO.22.01725">https://ascopubs.org/doi/10.1200/JCO.22.01725</a>
Wang M, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial. <i>Lancet.</i> 2018;391:659-667.	<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33108-2/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)33108-2/fulltext</a>
Wang ML, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. <i>Blood.</i> 2015;126:739-745.	<a href="https://ashpublications.org/blood/article/126/6/739/34612/Long-term-follow-up-of-MCL-patients-treated-with">https://ashpublications.org/blood/article/126/6/739/34612/Long-term-follow-up-of-MCL-patients-treated-with</a>
Wang XV, et al. Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib. <i>Blood.</i> 2021;138:2810-2827.	<a href="https://ashpublications.org/blood/article/138/26/2810/476606/Measurable-residual-disease-does-not-preclude">https://ashpublications.org/blood/article/138/26/2810/476606/Measurable-residual-disease-does-not-preclude</a>
Zhou K, et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: A pooled analysis of two clinical trials. <i>J Hematol Oncol.</i> 2021;14:167.	<a href="https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01174-3">https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01174-3</a>
Zhu M, et al. Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignancies. <i>Clin Transl Sci.</i> 2022;15:954-966.	<a href="https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13212">https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13212</a>
Zugmaier G, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. <i>Blood Cancer J.</i> 2014;4(9):244.	<a href="https://www.nature.com/articles/bcj201464">https://www.nature.com/articles/bcj201464</a>